The statement said the scientific critique details why Merck disagrees with analysis of The Lancet and added that until a study this year, "data from Merck's clinical trials showed no significant difference in cardiovascular risk" of Vioxx.
s new pain reliever, Arcoxia, was gentler on the stomach than an older pain reliever, the drug maker said as it released results of a new study Tuesday.
Merck shares were down $3.19, or 10.2 percent, at $28.12 on the New York Stock Exchange after The Wall Street Journal reported that internal e-mails and marketing materials show the company knew as far back
